The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14160%2F24%3A00135350" target="_blank" >RIV/00216224:14160/24:00135350 - isvavai.cz</a>
Výsledek na webu
<a href="https://www.valuehealthregionalissues.com/article/S2212-1099(23)00109-7/fulltext" target="_blank" >https://www.valuehealthregionalissues.com/article/S2212-1099(23)00109-7/fulltext</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.vhri.2023.10.001" target="_blank" >10.1016/j.vhri.2023.10.001</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment
Popis výsledku v původním jazyce
Objectives: This article aimed to count and compare treatment's direct (only biological drugs) and indirect (loss of productivity) costs in patients with rheumatoid arthritis from 2019 to 2021.Methods: The friction cost approach was used to establish indirect costs. Elasticity factor values and friction period for the Slovak Republic from 2019 to 2021 were determined. Direct drug costs were calculated based on average prices from 2019 to 2021 and the number of dispensed medication packages.Results: The average productivity loss reached euro2984.54 in 2019, euro3338.46 in 2020, and euro3154.01 in 2021. Total indirect costs include productivity loss and sick pay, and from 2019 to 2021 came the values of euro8.4 million, euro10.1 million, and euro8.1 million, respectively. Conclusions: Indirect costs were almost 2.5 to 3 times lower than the biological and targeted treatment costs.
Název v anglickém jazyce
The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment
Popis výsledku anglicky
Objectives: This article aimed to count and compare treatment's direct (only biological drugs) and indirect (loss of productivity) costs in patients with rheumatoid arthritis from 2019 to 2021.Methods: The friction cost approach was used to establish indirect costs. Elasticity factor values and friction period for the Slovak Republic from 2019 to 2021 were determined. Direct drug costs were calculated based on average prices from 2019 to 2021 and the number of dispensed medication packages.Results: The average productivity loss reached euro2984.54 in 2019, euro3338.46 in 2020, and euro3154.01 in 2021. Total indirect costs include productivity loss and sick pay, and from 2019 to 2021 came the values of euro8.4 million, euro10.1 million, and euro8.1 million, respectively. Conclusions: Indirect costs were almost 2.5 to 3 times lower than the biological and targeted treatment costs.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30104 - Pharmacology and pharmacy
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2024
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Value in Health Regional Issues
ISSN
2212-1099
e-ISSN
—
Svazek periodika
40
Číslo periodika v rámci svazku
March
Stát vydavatele periodika
NL - Nizozemsko
Počet stran výsledku
6
Strana od-do
13-18
Kód UT WoS článku
001117176500001
EID výsledku v databázi Scopus
—